- Home
- TCPC vs LYEL Comparison
TCPC vs LYEL Comparison
Compare TCPC & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCPC | LYEL |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.6M | 504.8M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TCPC | LYEL |
|---|---|---|
| Price | $4.83 | $23.85 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $6.50 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.2M | 89.3K |
| Earning Date | 02-27-2026 | 03-10-2026 |
| Dividend Yield | ★ 23.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $219,119,058.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.76 | $7.65 |
| 52 Week High | $9.48 | $45.00 |
Technical Indicators
Market Signals| Indicator | TCPC | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 34.36 | 46.67 |
| Support Level | $4.76 | $21.95 |
| Resistance Level | $4.93 | $25.18 |
| Average True Range (ATR) | 0.17 | 2.05 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 9.23 | 55.01 |
Price Performance
Historical ComparisonAbout TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.